Compare ARK Genomic Revolution ETF (ARKG) vs QUALCOMM, Inc. (QCOM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Genomic Revolution ETF vs QUALCOMM, Inc. — how do they compare? ARK Genomic Revolution ETF trades at $41.24, while QUALCOMM, Inc. trades at $184.5 (market cap $199.37B). The key difference: QUALCOMM, Inc. pays a 1.95% dividend while ARK Genomic Revolution ETF pays none, and ARK Genomic Revolution ETF is trading nearer its 52-week high, QUALCOMM, Inc. nearer its low. Which is the better fit depends on your goals.
| ARKG | QCOM | |
|---|---|---|
Sector | Sector/Thematic | Technology |
52-Week High | $43.57 | $251.10 |
52-Week Low | $23.09 | $124.07 |
Market Cap | — | $199.37B |
Enterprise Value | — | $204.85B |
Dividend Yield | — | 1.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
Qualcomm (QCOM) trades at $189.16, down 1.01% over the past 24 hours, with a bullish technical signal from moving averages and a neutral oscillator reading. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.56 estimate. Revenue for 2025 reached $44.28 billion, though net income margin compressed to 12.51% from prior years. Recent news highlights Qualcomm's push into AI and data centers, including the 'Dragonfly' AI brand launch at COMPUTEX 2026.
The outlook for QCOM is cautiously optimistic, with a consensus price target of $221.21 implying 17% upside. Opportunities include diversification into automotive and AI inference markets, but risks persist from smartphone demand softness and competitive pressure from Nvidia's entry into PC chips. Analyst sentiment is mixed, with 42.65% buy ratings amid margin concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About QUALCOMM, Inc.
Qualcomm develops and licenses wireless technology and designs chips for smartphones. The company's key patents revolve around CDMA and OFDMA technologies, which are standards in wireless communications that are the backbone of all 3G and 4G networks. The firm is a leader in 5G network technology as well. Qualcomm's IP is licensed by virtually all wireless device makers. The firm is also the world's largest wireless chip vendor, supplying nearly every premier handset maker with leading-edge processors. Qualcomm also sells RF-front end modules into smartphones and chips into automotive and Internet of Things markets.
Read more on QCOM →
